Agios Pharmaceuticals (AGIO) Amortization of Deferred Charges (2019 - 2021)

Agios Pharmaceuticals (AGIO) has 6 years of Amortization of Deferred Charges data on file, last reported at $3.3 million in Q2 2026.

• Quarterly Amortization of Deferred Charges rose 7.96% year-over-year to $3.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.9 million (up 7.9% YoY) and the FY2025 annual result came in at $12.4 million, up 7.76% from the prior year.
• Amortization of Deferred Charges climbed to $3.3 million in Q2 2026, from $3.3 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $3.3 million in Q2 2026 to a low of $2.4 million in Q1 2022.
• A 5-year average of $2.8 million and a median of $2.8 million in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges rose 0.79% — and 2026, when it rose 7.96%.
• Tracing AGIO's Amortization of Deferred Charges over 5 years: stood at $2.6 million in 2022, then increased by 7.41% to $2.8 million in 2023, then advanced by 7.59% to $3.0 million in 2024, then gained by 7.9% to $3.2 million in 2025, then increased by 3.91% to $3.3 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $3.3 million (Q2 2026), $3.3 million (Q1 2026), and $3.2 million (Q4 2025), per Business Quant data.